Breaking Down Barriers In Cell Therapy Manufacturing

Safety and cost have traditionally been the biggest challenges in cell therapy production. This has recently led the industry to prioritize reducing complexity. A by-product of several groups attempting to do this at once is a lack of standardization across the cell therapy production sector. A related challenge that developers face is that there's zero failure tolerance with the production of these therapeutics, resulting in manufacturing failure rates as high as 9% for some CAR T cell programs. The industry is coming up with several innovative workflows and solutions to scale up production of T cell and other cell therapies while meeting these challenges, resulting in the growth of some automated platforms such as the CTS DynaCellect system.